Impact of patient and plan design factors on switching to preferred statin therapy

Annals of Pharmacotherapy

Volumn 41, Issue 12, 2007, Pages 1946-1953

  Cox, Emily R ^a   Kulkarni, Amit ^a   Henderson, Rochelle ^a  

^a Express Scripts   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; BIVARIATE ANALYSIS; CLINICAL PHARMACY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; COVARIANCE; DRUG FORMULARY; DRUG PREFERENCE; DRUG SUBSTITUTION; FEMALE; HEALTH INSURANCE; HOME CARE; HUMAN; INTERNET; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT CARE; PHARMACY; PHARMACY BENEFIT MANAGER; PREDICTION; PRIORITY JOURNAL; TELEPHONE; TREATMENT PLANNING;

DRUGS, GENERIC; FEMALE; FORMULARIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PRESCRIPTION FEES; PYRROLES;

EID: 36849048637     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K253     Document Type: Article

References (17)

1. Employer Health Benefits-2006 annual survey. The Kaiser Family Foundation and Health Research and Education Trust. http://athensbenefits.com/pdf/ 2006_10_06_Employer_Health_Benefit_Survey_2006.pdf (accessed 2007 Jan 10).
2. Ganther-Urmie JM, Nair KV, Valuck R, McCollum M, Lewis SJ, Turpin RS. Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans. Am J Manag Care 2004;10:201-8.
3. Rector TS, Finch MD, Danzon PM, Pauly MV, Manda BS. Effect of tiered prescription copayments on the use of preferred brand medications. Med Care 2003;41:398-406. DOI 10.1097/00005650-200303000-00007
4. Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. J Manag Care Pharm 2003;9:123-33.
5. Fairman KA, Motheral BR, Henderson RR. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Ther 2003;25:3147-61. DOI 10.1016/S0149-2918(03)90099-3
6. Huskamp HA., Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive based formularies on prescription-drug utilization and spending. N Engl J Med 2003;349:2224-32. DOI 10.1056/NEJMsa030954
7. Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care 2005;11:621-8.
8. Gilman BH, Kautter J. Consumer response to dual incentives under multitiered prescription drug formularies. Am J Manag Care 2007;13(6 pt 2):353-9.
9. Delate T, Henderson R. Effect of patient notification of formulary change on formulary adherence. J Manag Care Pharm 2005;11:493-8.
10. Billups SJ, Plushner SL, Olson KL, Koehler TJ, Kerzee J. Clinical and economic outcomes of conversion of simvastatin to lovastatin in a group-model health maintenance organization. J Manag Care Pharm 2005;11:681-6.
11. Recto CS, Acosta S, Dobs A. Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia. Clin Cardiol 2000;23:682-8.
12. Pedersen RT, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: a randomized controlled trial. JAMA 2005;294:2437-45.
13. National Drug Data File Plus. San Bruno, CA: First Data Bank, 2006.
14. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick MA. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004;19:638-45. DOI 10.1111/j.1525-1497.2004.30516.x
15. Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. Am J Manag Care 2006;12:509-17.
16. Mager DE, Cox ER. Relationship between generic and preferred-brand prescription copayment differentials and generic fill rate. Am J Manag Care 2007;13(6 pt 2):347-52.
17. Fox S. Online health search 2006. Washington, DC: Pew Internet & American Life Project, October 29, 2006.